We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An antitrust lawsuit filed in a federal court in New York claims AstraZenica struck a deal with generic drugmakers to hold off on launching versions of its anti-psychotic drug Seroquel XR. Read More
Allergan has agreed to pay $2.74 million to three labor union health funds in a bid to bring antitrust litigation against the drugmaker to a close. The payments, revealed in documents filed in the U.S. District Court for Massachusetts, resolves claims from certain plaintiffs that alleged anticompetitive behavior related to the ulcerative colitis drug Asacol (mesalamine). Read More
Teva used four pay-for-delay agreements to illegally control sales of the drug between 2006 and 2012 and drove up the cost of the drug, the state’s attorney general said. Read More
Israeli drug titan Teva Pharmaceuticals and two other drugmakers have agreed to settlements in California in order to shake allegations of anticompetitive pay-for-delay deals. Read More
In a big week for Pfizer, the world’s second largest drugmaker earned the FDA’s approval for a biosimilar cancer treatment and signed up the agency’s former Commissioner Scott Gottlieb for its board. Read More
Eli Lilly’s lower-cost generic of its blockbuster insulin drug Humalog (insulin lispro) hit pharmacies on Wednesday following months of heat from both Congress and the White House over high insulin drug prices. Read More
The jury awarded Guo $1.8 million in damages, but it also found that she had violated company policy in her handling of the dispute and awarded Novartis damages. Read More
Novartis is hinting that it will appeal a New Jersey jury’s verdict awarding $1.5 million to a former executive who alleged that the company created a bogus drug study to disguise kickbacks to a leading drug distributor. Read More